Objective:To investigate the clinical effect of amiodarone on patients with atrial fibrillation after heart valve replacement, and to provide reference basis for improving the efficacy of patients with atrial fibrillation after heart valve replacement.Methods:The PubMed, Web of Science, WILEY medical and nursing discipline database, Cochrane Library, CNKI, Wanfang database, VIP database and China Biology Medicine disc were searched by computer. Randomized controlled trials (RCTs) about amiodarone treating patients with atrial fibrillation after heart valve replacement were searched from the establishment of the database to 24th September , 2019. After two people's independent literature screening and literature quality evaluation, relevant data were extracted and quantitative comprehensive analysis was conducted with Revman 5.3 software.Results:A total of 7 articles were included, including 6 Chinese articles and 1 English article. There were 710 patients in total, including 363 cases in the experimental group and 347 cases in the control group. Quantitative synthesis was performed with Revman 5.3 software, and the results showed that amiodarone treatment for atrial fibrillation after valve replacement could improve the recovery rate of atrial fibrillation ( RR=1.36, 95% CI: 1.20-1.54, P<0.05) . The rate of sinus rhythm maintenance was increased ( RR=1.41, 95% CI: 1.16-1.72, P=0.002) , the ICU monitoring time was shortened ( MD=-1.09, 95% CI: -1.32--0.86, P<0.05) , and the total days in hospital was reduced ( MD=-3.92, 95% CI: -4.25--3.59, P<0.05) . Conclusions:Amiodarone treatment for atrial fibrillation after valve replacement can improve the recovery rate of atrial fibrillation and the rate of sinus rhythm maintenance, reduce the ICU monitoring time and the total days in hospital, which is worthy of clinical application.

Objective:To explore the best evidence of non-surgical management of stress urinary incontinence in women, so as to provide evidence for effective prevention and treatment of related diseases.Methods:According to the "6S" classification model of evidence-based retrieval resources, the researches on non-surgical management of female patients with stress urinary incontinence were retrieved in UpToDate, BMJ Best Practice, major guideline websites, professional association websites and other Chinese and English databases, including clinical decision-making, evidence-based guidelines, systematic reviews, expert consensus and randomized controlled trials. The search period was from establishment of databases to April 30, 2023.Results:A total of 13 articles were included, including three clinical decisions, five guidelines, one expert consensus and four systematic evaluations. The best evidence summarized included 27 items in four aspects, such as screening and evaluation, lifestyle behavior management, functional training and medication treatment.Conclusions:The best evidence for non-surgical management of female patients with stress urinary incontinence summarized in this study can provide guidance for clinical medical staff to manage female stress urinary incontinence scientifically and normatively. Medical personnel can apply this evidence according to the national conditions of China and patients' own conditions.

Recent studies have shown that the chemokine receptor CXCR3 and its ligand CXCL10 in the dorsal root ganglion mediate itch in experimental allergic contact dermatitis (ACD). CXCR3 in the spinal cord also contributes to the maintenance of neuropathic pain. However, whether spinal CXCR3 is involved in acute or chronic itch remains unclear. Here, we report that Cxcr3 mice showed normal scratching in acute itch models but reduced scratching in chronic itch models of dry skin and ACD. In contrast, both formalin-induced acute pain and complete Freund's adjuvant-induced chronic inflammatory pain were reduced in Cxcr3 mice. In addition, the expression of CXCR3 and CXCL10 was increased in the spinal cord in the dry skin model induced by acetone and diethyl ether followed by water (AEW). Intrathecal injection of a CXCR3 antagonist alleviated AEW-induced itch. Furthermore, touch-elicited itch (alloknesis) after compound 48/80 or AEW treatment was suppressed in Cxcr3 mice. Finally, AEW-induced astrocyte activation was inhibited in Cxcr3 mice. Taken together, these data suggest that spinal CXCR3 mediates chronic itch and alloknesis, and targeting CXCR3 may provide effective treatment for chronic pruritus.
Acetamides ; therapeutic use ; Animals ; Chemokine CXCL10 ; metabolism ; Chloroquine ; toxicity ; Chronic Disease ; Cyclopropanes ; adverse effects ; Dehydration ; complications ; Dinitrofluorobenzene ; adverse effects ; Disease Models, Animal ; Formaldehyde ; toxicity ; Freund's Adjuvant ; toxicity ; Mice ; Mice, Inbred C57BL ; Mice, Knockout ; Motor Activity ; drug effects ; Pain ; chemically induced ; Pruritus ; chemically induced ; pathology ; Pyrimidines ; therapeutic use ; Receptors, CXCR3 ; antagonists & inhibitors ; genetics ; metabolism ; Skin ; pathology ; Spinal Cord ; drug effects ; metabolism ; pathology ; Time Factors ; p-Methoxy-N-methylphenethylamine ; toxicity